BEAMTREE HOLDINGS LIMITED (BMT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BMT - BEAMTREE HOLDINGS LIMITED

FNArena Sector : Healthcare services

Year End: June

GICS Industry Group : Health Care Equipment & Services

Debt/EBITDA: -6.15

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.21 12 Nov 2025	0.010 OPEN $0.20	5.00% HIGH $0.21	211,086 LOW $0.20

TARGET

$0.60

185.7% upside

OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . DOC . EBO . HLS . IDX . M7T . MDR . MPL . MVF . NHF . RHC . SHL .

FNARENA'S MARKET CONSENSUS FORECASTS

Title	FY24 Actual	FY25 Actual	FY26 Forecast	FY27 Forecast
EPS (cps)	xxx	- 2.1	- 1.0	xxx
DPS (cps)	xxx	0.0	0.0	xxx
EPS Growth	xxx	N/A	N/A	xxx
DPS Growth	xxx	N/A	N/A	xxx
PE Ratio	xxx	N/A	N/A	xxx
Dividend Yield	xxx	N/A	0.0%	xxx
Div Pay Ratio(%)	xxx	N/A	N/A	xxx

Dividend yield today if purchased 3 years ago: 0.00%

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2020	2021	2022	2023	2024	2025
EPS Basic	xxx	xxx	xxx	xxx	xxx	-2.1
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	28.6 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	14.4
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	0.6 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-21.54 %

EPS Basic

Negative
Growth
Slowing

DPS All

Negative
Growth
Slowing

Sales/Revenue

Negative
Growth
Slowing

Book Value Per Share

Negative
Growth
Slowing

Net Operating Cash Flow

Negative
Growth
Slowing

Net Profit Margin

Negative
Growth
Slowing

Title	2020	2021	2022	2023	2024	2025
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-13.83 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-13.16 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-10.81 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-13.83 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-12.87 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	0.4 M

Return on Capital Employed

Negative
Growth
Slowing

Return on Invested Capital

Negative
Growth
Slowing

Return on Assets

Negative
Growth
Slowing

Return on Equity

Negative
Growth
Slowing

Return on Total Capital

Negative
Growth
Slowing

Free Cash Flow ex dividends

Negative
Growth
Slowing

Title	2020	2021	2022	2023	2024	2025
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	0 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	3 M
Total Debt	xxx	xxx	xxx	xxx	xxx	3 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	31 M
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	5 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	1.73

Short-Term Debt

Negative
Growth
Slowing

Long Term Debt

Negative
Growth
Slowing

Total Debt

Negative
Growth
Slowing

Goodwill - Gross

Negative
Growth
Slowing

Cash & Equivalents - Generic

Negative
Growth
Slowing

Price To Book Value

Negative
Growth
Slowing

Title	2020	2021	2022	2023	2024	2025
Capex	xxx	xxx	xxx	xxx	xxx	2.5 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	8.58 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	30 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	5 M
Research & Development	xxx	xxx	xxx	xxx	xxx	-
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Negative
Growth
Slowing

Capex % of Sales

Negative
Growth
Slowing

Cost of Goods Sold

Negative
Growth
Slowing

Selling, General & Admin. Exp & Other

Negative
Growth
Slowing

Research & Development

Investments - Total

Negative
Growth
Slowing

Negative

Growth

Slowing

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Shaw and Partners	16/10/2025	1	Buy	$0.60	185.71%	Shaw and Partners assesses Beamtree Holdings' 1Q26 update as solid and regards the appointment of Stuart MacDonald to its Board as a strategic positive. MacDonald is COO of TechnologyOne ((TNE)). Cost management was a highlight for the broker, with opex declining -2% y/y, and total cost growing 1%, well below the FY26 forecast of 4% and 8% growth, respectively. Recurring revenue grew 9% y/y, but the run-rate was well below the broker's FY26 estimate of 18% y/y growth. The company reiterated confidence in delivering further financial improvement through FY26. No change to forecasts. Buy, High Risk. Target unchanged at 60c. FORECAST Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents. Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.50 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Shaw and Partners

16/10/2025

Buy

$0.60

185.71%

Shaw and Partners assesses Beamtree Holdings' 1Q26 update as solid and regards the appointment of Stuart MacDonald to its Board as a strategic positive. MacDonald is COO of TechnologyOne ((TNE)).

Cost management was a highlight for the broker, with opex declining -2% y/y, and total cost growing 1%, well below the FY26 forecast of 4% and 8% growth, respectively.

Recurring revenue grew 9% y/y, but the run-rate was well below the broker's FY26 estimate of 18% y/y growth.

The company reiterated confidence in delivering further financial improvement through FY26.

No change to forecasts. Buy, High Risk. Target unchanged at 60c.

FORECAST
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.50 cents.

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Petra Capital	12/06/2025	1	Buy	$0.50	138.10%	Beamtree Holdings has secured a five-year partnership with the UK NHS Confederation, observes Petra Capital. This launches the Evolve Collaborative, a strategic partnership between Australian health technology company Beamtree and the UK’s NHS Confederation to deploy predictive analytics and benchmarking tools to up to 120 hospital trusts. The broker notes initial pricing is GBP50,000 per trust, with rollout from late-2025 and full implementation by January 2026, offering upside risk to FY27 revenue forecasts if uptake is strong. While no changes have been made to the analyst's earnings forecasts, Petra sees the opportunity as highly strategic. Potential downstream benefits are noted for Beamtree’s suite of hospital coding tools including PICQ and autonomous coding. Petra Capital retains a Buy rating and 50c target price. FORECAST Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.30 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Petra Capital

12/06/2025

Buy

$0.50

138.10%

Beamtree Holdings has secured a five-year partnership with the UK NHS Confederation, observes Petra Capital.

This launches the Evolve Collaborative, a strategic partnership between Australian health technology company Beamtree and the UK’s NHS Confederation to deploy predictive analytics and benchmarking tools to up to 120 hospital trusts.

The broker notes initial pricing is GBP50,000 per trust, with rollout from late-2025 and full implementation by January 2026, offering upside risk to FY27 revenue forecasts if uptake is strong.

While no changes have been made to the analyst's earnings forecasts, Petra sees the opportunity as highly strategic. Potential downstream benefits are noted for Beamtree’s suite of hospital coding tools including PICQ and autonomous coding.

Petra Capital retains a Buy rating and 50c target price.

FORECAST
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.30 cents.

Access Extra Coverage Research History >

BMT STOCK CHART

FNArena News on BMT

1	FNArena Corporate Results Monitor – 29-08-2025 Aug 29 2025 - Australia

2	Australian Broker Call Extra Edition – Jun 12, 2025 Jun 12 2025 - Daily Market Reports

3	Australian Broker Call Extra Edition – May 12, 2025 May 12 2025 - Daily Market Reports

4	Australian Broker Call Extra Edition – Feb 24, 2025 Feb 24 2025 - Daily Market Reports

5	FNArena Corporate Results Monitor – 22-02-2025 Feb 22 2025 - Australia

Latest Healthcare services News

1	Better Times Ahead For Sonic Healthcare? Jun 20 2025 - Australia

2	The Significance Of Cosmetique’s ASX Listing Feb 26 2025 - Small Caps

3	Building The No 3 Diagnostic Imaging Player Jun 19 2024 - Small Caps

4	Capitol Health’s Higher Margin Outlook Mar 13 2024 - Small Caps

5	Treasure Chest: Ramsay Health Care Oct 26 2023 - Treasure Chest

6	Timing Seems Right For Alcidion Group Jun 21 2023 - Small Caps

7	No Enthusiasm To Combine ACL & Healius Mar 21 2023 - Australia

8	Dr Boreham’s Crucible: Alcidion Dec 13 2022 - Small Caps

9	No Straight Covid-Relief For Ramsay Health Care Nov 15 2022 - Australia

10	Dr Boreham’s Crucible: Mach7 Technologies Nov 14 2022 - Small Caps

Dividend Yield Today On Last Actual Payout :	0.00
Estimated Dividend Growth (Average Of Past Three Years)	%
Amount Invested	$
Tell Me The Dividend After This Many Years

	Yield	Yield on investment
This Year
Year 1
Year 2
Year 3
Year 4
Year

1	FNArena Corporate Results Monitor – 29-08-2025 Aug 29 2025 - Australia

2	Australian Broker Call Extra Edition – Jun 12, 2025 Jun 12 2025 - Daily Market Reports

3	Australian Broker Call Extra Edition – May 12, 2025 May 12 2025 - Daily Market Reports

4	Australian Broker Call Extra Edition – Feb 24, 2025 Feb 24 2025 - Daily Market Reports

5	FNArena Corporate Results Monitor – 22-02-2025 Feb 22 2025 - Australia

Get 2 Weeks free trial

Sign Up

Member Login

BEAMTREE HOLDINGS LIMITED (BMT)
Share Price Analysis and Chart